Lexaria Bioscience (LEXX) Financial Statements
Lexaria Bioscience Financial Overview
Lexaria Bioscience's market cap is currently $7.35M. The company's EPS TTM is $-5.32; its P/E ratio is -0.66; Lexaria Bioscience has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Aug 25 | Aug 24 | Aug 23 | Aug 22 | Aug 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 705.92K | $ 464.28K | $ 226.21K | $ 255.40K | $ 722.74K |
| Gross Profit | $ 703.20K | $ 459.46K | $ 194.71K | $ 183.56K | $ 547.39K |
| Operating Income | $ -11.88M | $ -5.75M | $ -6.53M | $ -6.62M | $ -5.69M |
| EBITDA | $ -11.82M | $ -5.73M | $ -6.57M | $ -7.28M | $ -4.02M |
| Net Income | $ -11.90M | $ -5.80M | $ -6.66M | $ -7.27M | $ -4.03M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.97M | $ 6.56M | $ 1.48M | $ 6.16M | $ 11.75M |
| Total Assets | $ 4.18M | $ 8.87M | $ 3.08M | $ 7.83M | $ 13.27M |
| Total Debt | $ 109.32K | $ 137.37K | $ 163.97K | $ 49.99K | $ 97.32K |
| Net Debt | $ -1.69M | $ -6.36M | $ -1.19M | $ -5.76M | $ -10.82M |
| Total Liabilities | $ 1.57M | $ 1.21M | $ 403.91K | $ 201.44K | $ 203.26K |
| Stockholders' Equity | $ 2.99M | $ 8.04M | $ 3.04M | $ 7.95M | $ 13.27M |
| Cash Flow | |||||
| Free Cash Flow | $ -10.48M | $ -5.00M | $ -6.05M | $ -4.93M | $ -4.07M |
| Operating Cash Flow | $ -10.45M | $ -4.96M | $ -5.88M | $ -4.88M | $ -3.99M |
| Investing Cash Flow | $ -243.02K | $ -188.60K | $ -169.61K | $ -180.64K | $ 193.88K |
| Financing Cash Flow | $ 6.05M | $ 10.32M | $ 1.59M | $ -44.60K | $ 13.42M |
Currency in USD
